This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Bogaard, A. E.
Right arrow Articles by Stobberingh, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Bogaard, A. E.
Right arrow Articles by Stobberingh, E. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 110-118, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.110-118.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Effects of Flavophospholipol on Resistance in Fecal Escherichia coli and Enterococci of Fattening P

A. E. van den Bogaard,1* M. Hazen,1 M. Hoyer,2 P. Oostenbach,2 and E. E. Stobberingh1

Department of Medical Microbiology, University Maastricht, NL-6200 MD Maastricht, The Netherlands,1 Intervet Innovation GmbH, Zur Probstei, D-55270 Schwabenheim, Germany2

Received 5 April 2001/ Returned for modification 13 August 2001/ Accepted 2 October 2001

A "plasmid-curing effect" of multiresistant Escherichia coli by flavophospholipol, an antibiotic used as an antimicrobial growth promoter (AMGP) in animal feeds, has been reported to occur in vitro and in vivo under experimental conditions. In this study, the effect of flavophospholipol under field conditions was studied. The prevalence and degree (proportion of resistant strains to the total numbers present per gram of feces) of resistance of indicator bacteria, E. coli and enterococci, was determined in fecal samples from three groups of pigs that were fed a commercial finisher feed without any AMGP. Group A was the negative control group without any AMGP, group B received the same feed with 9 mg of flavophospholipol/kg of feed (study group), and group C received the same feed with 15 mg of avoparcin/kg (positive control). Fecal samples from each pig were collected at the start and at the end of the study and assessed for the prevalence and degree of resistance against antibiotics commonly used either for therapy in pig medicine or as an AMGP. Before the start of the study, all pigs were colonized with multiresistant E. coli by mixing three resistant pig isolates through their feed after disturbance of the colonization resistance of the intestinal flora by a 3-day course of lincomycin and spectinomycin. At the end of the study, the overall prevalence and degree of resistance of E. coli in the fecal flora had increased significantly in groups A and C but remained at the same level as at the start of the study in group B. The prevalence of vancomycin resistance was 44 and 41% in groups A and B, respectively, but only very low numbers of vancomycin-resistant enterococci (VRE) per gram of feces were found. In the avoparcin-fed group, the prevalence was 72%, and in 57% of the samples, more than 50% of all enterococci present were vancomycin resistant. The prevalence of resistant Enterococcus faecalis increased only in the flavophospholipol-exposed group, from 23% before the start of the study to 43% at the end of the study. It was concluded that flavophospholipol effectively suppressed the augmentation and dissemination of multiresistant E. coli in the intestinal flora of fattening pigs. Avoparcin use strongly selected for VRE carriage and excretion. Therefore, as neither flavophospholipol nor any related molecule is used therapeutically, no cross-resistance with therapeutic antibiotics exists and no transmissible resistance has been shown; the major decrease in resistance in intestinal E. coli of flavophospholipol-fed animals seemed to outweigh the small increase in the risk of transfer of flavophospholipol-resistant E. faecalis from animals to humans via the food chain.

* Corresponding author. Mailing address: Department of Medical Microbiology, University Maastricht, P.O. Box 616, NL-6200 MD Maastricht, The Netherlands. Phone: 31.43.3881015. Fax: 31.43.3884161. E-mail: A.vandenBogaard{at}CPV.Unimaas.NL.

Antimicrobial Agents and Chemotherapy, January 2002, p. 110-118, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.110-118.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Poole, T. L., McReynolds, J. L., Edrington, T. S., Byrd, J. A., Callaway, T. R., Nisbet, D. J. (2006). Effect of flavophospholipol on conjugation frequency between Escherichia coli donor and recipient pairs in vitro and in the chicken gastrointestinal tract. J Antimicrob Chemother 58: 359-366 [Abstract] [Full Text]  
  • Butaye, P., Devriese, L. A., Haesebrouck, F. (2003). Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria. Clin. Microbiol. Rev. 16: 175-188 [Abstract] [Full Text]  
  • Bruinsma, N., Willems, R. J. L., van den Bogaard, A. E., van Santen-Verheuvel, M., London, N., Driessen, C., Stobberingh, E. E. (2002). Different Levels of Genetic Homogeneity in Vancomycin-Resistant and -Susceptible Enterococcus faecium Isolates from Different Human and Animal Sources Analyzed by Amplified-Fragment Length Polymorphism. Antimicrob. Agents Chemother. 46: 2779-2783 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»